Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.
about
Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolitesDose dependent effects on cell cycle checkpoints and DNA repair by bendamustinePurine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignanciesBendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours.Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma.Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: efficacy and tolerability.Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.Role of bendamustine in the treatment of chronic lymphocytic leukemia.Severe Liver Damage and Nonallergic Bronchitis with Eosinophilia in a Patient with Follicular Lymphoma Treated with Bendamustine plus Rituximab.Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancyThe role of bendamustine in the treatment of indolent non-Hodgkin lymphomaBendamustine: safety and efficacy in the management of indolent non-hodgkins lymphomaMulticenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial.Bendamustine in patients with relapsed or refractory multiple myeloma.Inhibition of STAT3 by Anticancer Drug BendamustineTargeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agentsManagement of relapsed chronic lymphocytic leukemia: applying guidelines to practiceNavitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.Chemotherapy induced DNA damage response: convergence of drugs and pathwaysDetermination of Bendamustine in Human Plasma and Urine by LC-FL Methods: Application in a Drug MonitoringBendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working PartyBendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block.Bendamustine in the treatment of non-Hodgkin's lymphomas.Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis.Japanese apricot extract (MK615) potentiates bendamustine-induced apoptosis via impairment of the DNA damage response in lymphoma cells.Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin's lymphoma.Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline.
P2860
Q27011795-CA609BE1-E16D-4891-A253-80E2F190EF9CQ27335118-F746A606-D804-43BC-973B-79FAB52CAC11Q28540830-80C49EB0-1D4D-4D03-A8A6-5683EEDD454AQ30435188-C2A66229-0D6E-46AE-A44E-B6DD6F9F9B74Q33375169-953DB68D-CC39-4531-9E45-9BB439382330Q33388177-C2DEAE81-BE05-4181-9B41-F6A65E2AE7B4Q33410592-CD2BAC52-2E7D-4707-B8C5-AD97AC35207AQ33411708-DFBD3B45-C16F-40FF-9432-59548AA4E7B6Q33916026-4D6E6EC3-85C4-4E77-9ADB-16D8892CD3EFQ34181244-42897B2E-CCB5-49E3-8957-E9959FC6CF5BQ34322781-B9E89BE3-5688-401D-8E84-8531CA3EF08EQ34418442-9522C019-FC5B-4176-AB4E-26FEBB91A893Q35052538-175AF3BD-D9C0-430D-AD71-619324CF8A69Q35789406-5D45E989-3DF9-4F77-9FAE-82065EE18CBCQ35958553-262207C5-A720-4871-A461-E71DEEF27630Q36261308-28A8A6FB-F078-4461-A87E-96CDB015DC8EQ36293814-8B4470A0-BB9B-4BBD-A9B4-60337FED1B10Q36521032-D25A2CFF-640B-4B75-BD20-F306422DB125Q36619787-5BDB5698-6447-43DE-8DE9-2B3B702399E1Q36901484-8A836CBA-CEDA-4B74-B5C6-35E0BF36BAC8Q37059359-D87ACAD7-C157-4D71-9795-EFFF45B1E36CQ37318682-7C4A016F-037A-406E-9BB4-A4590DD286E8Q37480786-BCA099C8-A9C0-4277-95AA-10FC06D73704Q37771253-155B82F6-E803-44FA-902E-0FEDB2330742Q38660743-93C7E86F-BC9E-4602-9DF8-083113F3794BQ40978733-FAF30114-AE73-4505-B11C-8D5591DDFF33Q43203237-67411D68-A34A-462B-9803-0D0BEAB5B654Q52563039-FC8170D8-1B7A-437D-863F-BCC47D0275C0
P2860
Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Bendamustine hydrochloride act ...... n breast carcinoma cell lines.
@ast
Bendamustine hydrochloride act ...... n breast carcinoma cell lines.
@en
Bendamustine hydrochloride act ...... n breast carcinoma cell lines.
@nl
type
label
Bendamustine hydrochloride act ...... n breast carcinoma cell lines.
@ast
Bendamustine hydrochloride act ...... n breast carcinoma cell lines.
@en
Bendamustine hydrochloride act ...... n breast carcinoma cell lines.
@nl
prefLabel
Bendamustine hydrochloride act ...... n breast carcinoma cell lines.
@ast
Bendamustine hydrochloride act ...... n breast carcinoma cell lines.
@en
Bendamustine hydrochloride act ...... n breast carcinoma cell lines.
@nl
P2093
P1433
P1476
Bendamustine hydrochloride act ...... an breast carcinoma cell lines
@en
P2093
P304
P356
10.1097/00001813-199606000-00007
P577
1996-06-01T00:00:00Z